Fig. 7

ATM deficiency enhances inhibitory effect of PARPi in NB cells. Olaparib-treated CRISPR-Ctrl and -ATM cells were evaluated for viability. Cells were plated at 3000 cells/well/100 µL. WST-8 assays were performed 72 h after olaparib treatment. DMSO was used as a negative control. A, B ATM-KO NGP cells and ATM haploinsufficient CHP-134 cells against olaparib viability, respectively. Data are shown as mean ± SD from three independent repeats. Statistical significance was calculated using the two-tailed paired Student’s t-test, where *p ≤ 0.05, **p ≤ 0.01, and N.S, not significant